COMMUNIQUÉS West-GlobeNewswire

Amneal Pharmaceuticals Added to S&P SmallCap 600® Index
28/01/2026
BRIDGEWATER, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has been added to the S&P SmallCap 600 ® Index. The inclusion will [...]
Elevar Therapeutics Submits New Drug Application to FDA for Lirafugratinib as Second-Line Treatment Option for Cholangiocarcinoma
28/01/2026
FORT LEE, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and [...]
Women’s Health Collective Canada Announces Vital Talks Event on Menstruation and Lifelong Hormonal Health, Presented by Vichy Laboratoires
28/01/2026
From menstrual cycles to menopause and beyond – experts explore how hormones shape health at every stage of life TORONTO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Women’s Health Collective Canada is pleased to announce the [...]
Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson’s disease
28/01/2026
- Phase 1b clinical site start-up and regulatory activities in Australia underway to support the global registrational program - HUNTSVILLE, AL, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or [...]
Senseonics Holdings, Inc. to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
28/01/2026
GERMANTOWN, Md., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose [...]
MEDVI Quad Prescription Information Updated as Consumer Interest in Prescription Erectile Dysfunction Treatment Access Through Telehealth Platforms Grows in 2026
28/01/2026
An informational overview examining category context, publicly available service disclosures, and what consumers often consider when researching prescription erectile dysfunction treatment access through telehealth [...]
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update
28/01/2026
First patients dosed in DAYBreak™ registrational program for bexobrutideg in relapsed/refractory CLL Presented Phase 1 results at ASH 2025 that support bexobrutideg’s potential best-in-class profile in relapsed/ [...]
Siren Biotechnology Announces FDA Clearance of First IND, Advancing Company to Clinical Stage
28/01/2026
SAN FRANCISCO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s [...]
NADP Foundation Announces 2026 Grants
28/01/2026
DALLAS, Jan. 28, 2026 (GLOBE NEWSWIRE) -- The National Association of Dental Plans (NADP) Foundation is pleased to announce the recipients of its 2026 grant awards, supporting innovative projects that improve access to [...]
Guerbet: Karim Boussebaa appointed Chief Executive Officer
28/01/2026
Karim Boussebaa Appointed Chief Executive Officer of Guerbet Villepinte, January 28, 2026: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, announces the appointment [...]
GUERBET : Karim Boussebaa nommé Directeur général
28/01/2026
Karim Boussebaa nommé Directeur général de Guerbet Villepinte, le 28 janvier 2026 : Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l’imagerie médicale, annonce la nomination [...]
Memorial Şişli Hospital Earns EARL “Theranostics Center of Excellence” for Nuclear Oncology Treatments
28/01/2026
ISTANBUL, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Memorial Şişli Hospital’s (part of Memorial Hospitals Group ) Nuclear Medicine Department, Theranostics Unit has successfully completed the evaluation process under the [...]
Life Biosciences Announces FDA Clearance of IND Application for ER-100 in Optic Neuropathies
28/01/2026
IND clearance marks the first ever cellular rejuvenation therapy using partial epigenetic reprogramming to reach human clinical trials BOSTON, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Life Biosciences , Inc., (“Life Bio”) a [...]
Bexorg Awarded Grant from The Michael J. Fox Foundation to Identify Translational Biomarkers for TRPML1-Targeted Parkinson’s Disease Therapies
28/01/2026
- TRPML1 is a promising target 1 for Parkinson’s disease treatments and identifying translational biomarkers will help confirm target engagement in clinical studies - Bexorg will leverage its postmortem whole-human [...]
Nautilus Biotechnology and Weill Cornell Medicine-Qatar Collaborate with The Michael J. Fox Foundation to Advance Single-Molecule Proteomics Research in Parkinson’s Disease
28/01/2026
• Support from The Michael J. Fox Foundation for Parkinson’s Research to advance critical research into Parkinson’s disease biology • Nautilus’ development of a single-molecule assay for measuring alpha-synuclein [...]
Cannara annonce l'approbation conditionnelle de sa migration vers la Bourse de Toronto
28/01/2026
MONTRÉAL, 28 janv. 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara », la « Société », « nous » ou « notre ») ( TSXV : LOVE ) ( OTCQX : LOVFF ) ( FRA : 8CB0 ), producteur verticalement intégré de cannabis de [...]
Intelligent Bio Solutions Initiates Additional Clinical Studies for FDA 510(k) Submission Supporting Planned Entry into Multi-Billion Dollar U.S. Market
28/01/2026
Clinical studies designed to support FDA clearance and planned commercial launch into the world’s largest drug screening market Company anticipates full data analysis by the end of March 2026; data to be incorporated [...]
Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026
28/01/2026
Company intends to file an IND in Q4 2026 for its first RedTail lead candidate, CLD-401, a systemically delivered and targeted genetic medicine engineered to deliver high concentrations of IL-15 superagonist to the [...]
SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)
28/01/2026
This cross-disciplinary meeting highlights the latest discoveries, technologies and translational strategies driving the next generation of antimicrobial solutions JERSEY CITY, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- [...]

Pages